BRISTOL-MYERS SQUIBB COMPANY Onderneming Bristol-Myers Squibb Company Berne S.E.
Aandelen
BMY
US1101221083
Farmaceutische producten
|
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 44,08 CHF | +2,55% |
|
-.--% | -6,91% |
Vakgebied
De Verenigde Staten zijn goed voor 70,1% van de netto-omzet.
Verkoop per activiteit
| USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
|---|---|---|---|---|---|
Innovative Medicines
100,0
%
| 46 159 | 100,0 % | 45 006 | 100,0 % | -2,50% |
Verkoop per regio
| USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
|---|---|---|---|---|---|
United States
70,1
%
| 31 828 | 69,0 % | 31 555 | 70,1 % | -0,86% |
International
28,3
%
| 13 497 | 29,2 % | 12 752 | 28,3 % | -5,52% |
Other
1,6
%
| 834 | 1,8 % | 699 | 1,6 % | -16,19% |
Managers
| Managers | Titel | Leeftijd | Van |
|---|---|---|---|
| Chief Executive Officer | 53 | 01-02-15 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 20-11-19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Compliance Officer | - | 01-01-03 | |
| Chief Tech/Sci/R&D Officer | - | - | |
Samit Hirawat
CTO | Chief Tech/Sci/R&D Officer | 55 | 01-01-19 |
Robert Plenge
CTO | Chief Tech/Sci/R&D Officer | 53 | 01-11-19 |
Laura Hortas
IRO | Public Communications Contact | - | - |
| Corporate Officer/Principal | - | - | |
Cari Gallman
PRN | Corporate Officer/Principal | - | - |
Besturend
| Besturend | Titel | Leeftijd | Van |
|---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 20-11-19 |
Peter Arduini
BRD | Director/Board Member | 59 | 01-04-16 |
Derica Rice
BRD | Director/Board Member | 59 | 01-09-20 |
Paula Price
BRD | Director/Board Member | 62 | 01-09-20 |
Theodore Samuels
BRD | Director/Board Member | 69 | 21-02-17 |
David Elkins
DFI | Director of Finance/CFO | 55 | 20-11-19 |
| Chief Executive Officer | 53 | 01-02-15 | |
Julia Haller
BRD | Director/Board Member | 69 | 20-11-19 |
Karen Vousden
BRD | Director/Board Member | 66 | 01-01-18 |
| Director/Board Member | 56 | 01-06-21 |
Aandelenklasse
| Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
|---|---|---|---|---|---|
| Aandeel A | 1 | 2 923 100 096 | 2 024 918 592 ( 69,27 %) | 896 000 000 ( 30,65 %) | 69,27 % |
Participaties
| Naam | Aandelen | % | Totale waarde |
|---|---|---|---|
| 5 075 304 | 5.31% | 136 322 665 $ | |
| 759 145 | 6.36% | 19 358 198 $ | |
COMPUGEN LTD. 5.31% | 4 757 058 | 5.31% | 10 322 816 $ |
CELULARITY INC. 5.49% | 1 195 327 | 5.49% | 3 717 467 $ |
Bedrijfsgegevens
Bristol Myers Squibb Co.
Route 206 & Province Line Road
08543, Princeton
+609 252 4621
http://www.bms.com
Bedrijven van de groep
| Naam | Categorie en sector |
|---|---|
Bristol-Myers Squibb Pharmaceuticals Ltd.
 Bristol-Myers Squibb Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Pharmaceuticals Ltd. manufactures pharmaceutical products. Its products are used for treatment of diseases like cancer, diabetes, arthritis, hepatitis, and psychiatric disorders. The company distributes products throughout the United Kingdom. Bristol-Myers Squibb Pharmaceuticals was founded in 1989 and is located in Uxbridge, UK. |
Pharmaceuticals: Major
|
Celgene Alpine Investment Co. LLC
| |
Bristol-Myers Squibb SARL
 Bristol-Myers Squibb SARL Medical DistributorsDistribution Services Bristol-Myers Squibb SARL engages in the research, development, manufacture, and distribution of pharmaceutical products. Its therapeutic areas include immunoscience, immune-oncology, and cardiology. The company is headquartered in Rueil-Malmaison, France. |
Medical Distributors
|
Bristol-Myers Squibb Holdings Ireland Unlimited Co.
 Bristol-Myers Squibb Holdings Ireland Unlimited Co. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Holdings Ireland Unlimited Co., a subsidiary of Bristol Myers Squibb Co., is a company headquartered in Ireland that operates as a holding company which develops medicines for serious diseases. |
Pharmaceuticals: Major
|
Bristol-Myers Squibb Australia Pty Ltd.
 Bristol-Myers Squibb Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Australia Pty Ltd. is a biopharmaceutical company that researches, develops and markets medicines for serious diseases. The company was founded in 1930 and is headquartered in Noble Park North, Australia. |
Pharmaceuticals: Major
|
Bristol-Myers Squibb (Finland) Oy Ab
 Bristol-Myers Squibb (Finland) Oy Ab Pharmaceuticals: GenericHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb (Finland) Oy Ab is a Finnish pharmaceutical manufacturing company. The company is based in Vantaa, Finland. The company was founded in 1974. Simone Böhrer has been the CEO of the company since 2020. |
Pharmaceuticals: Generic
|
Bristol-Myers Squibb Belgium SA
 Bristol-Myers Squibb Belgium SA Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb Belgium SA develops, manufactures and distributes medicines. The company is based in Watermael-Boitsfor, Belgium. The CEO of the Belgian company is Paul Lacante. |
Pharmaceuticals: Major
|
Bristol-Myers Squibb de México S de RL de CV
 Bristol-Myers Squibb de México S de RL de CV Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb de México S de RL de CV is a Mexican company that manufactures and supplies pharmaceutical and nutritional products. The company is located in Mexico. |
Pharmaceuticals: Major
|
Bristol-Myers Squibb AB
 Bristol-Myers Squibb AB Medical DistributorsDistribution Services Part of Bristol Myers Squibb Co., Bristol-Myers Squibb AB is a company that wholesales medical equipment and pharmacy. The company is based in Solna, Sweden. |
Medical Distributors
|
Sector
Verkoop per regio
Herzieningen van WPA
| Vaira. 1 jan. | Kapi. | |
|---|---|---|
| +50,70% | 791 mld. | |
| +41,96% | 630 mld. | |
| -7,15% | 350 mld. | |
| +18,77% | 328 mld. | |
| +8,79% | 298 mld. | |
| +18,02% | 246 mld. | |
| +1,27% | 225 mld. | |
| +11,95% | 218 mld. | |
| +3,68% | 160 mld. |
